Related Experiment Videos
Sumanirole Pharmacia.
1Psychiatry Department, MCN AA-2213, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Tomas.dePaulis@vanderbilt.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|March 11, 2003
Summary
Sumanirole, a novel dopamine D2 agonist, is being developed for Parkinson's disease treatment. Clinical trials are progressing in Japan and the US.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease is a progressive neurodegenerative disorder.
- Dopamine agonists are a key therapeutic class for Parkinson's disease.
Purpose of the Study:
- To evaluate the efficacy and safety of Sumanirole, a dopamine D2 agonist.
- To advance Sumanirole through clinical development for Parkinson's disease.
Main Methods:
- Phase II clinical trials in Japan.
- Phase III clinical trials in the US.
Main Results:
- Sumanirole is currently in active clinical development.
- Data from ongoing trials will determine its therapeutic potential.
Conclusions:
- Sumanirole shows promise as a treatment for Parkinson's disease.
- Further clinical evaluation is necessary to establish its role in therapy.